Shanghai Aisar Biotechnology

Aisar Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of next-generation cell therapies for solid tumors. The company leverages its proprietary technology platforms to engineer CAR-T and TCR-T cells with enhanced persistence and infiltration capabilities within the immunosuppressive tumor microenvironment. Their lead programs target high-value antigens such as Glypican-3 and Claudin 18.2, aiming to address significant unmet needs in gastrointestinal and liver cancers. Aisar Bio is distinguished by its focus on armored CAR-T designs that incorporate metabolic reprogramming to improve clinical efficacy and T-cell fitness. The company maintains state-of-the-art R&D and manufacturing facilities in the Zhangjiang Hi-Tech Park to support its growing pipeline of innovative immunotherapies.